Wordt geladen...
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
BACKGROUND: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We ai...
Bewaard in:
| Gepubliceerd in: | Lancet Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5875180/ https://ncbi.nlm.nih.gov/pubmed/29248236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30906-3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|